Barclays PLC acquired a new stake in TherapeuticsMD Inc (NASDAQ:TXMD) during the third quarter, according to its most recent filing with the SEC. The firm acquired 98,034 shares of the company’s stock, valued at approximately $355,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Cetera Advisors LLC boosted its position in TherapeuticsMD by 11.1% in the 3rd quarter. Cetera Advisors LLC now owns 104,975 shares of the company’s stock valued at $384,000 after buying an additional 10,450 shares during the last quarter. Moloney Securities Asset Management LLC boosted its position in TherapeuticsMD by 42.9% in the 3rd quarter. Moloney Securities Asset Management LLC now owns 15,000 shares of the company’s stock valued at $54,000 after buying an additional 4,500 shares during the last quarter. Sigma Planning Corp bought a new position in TherapeuticsMD in the 3rd quarter valued at $42,000. California Public Employees Retirement System boosted its position in TherapeuticsMD by 15.0% in the 3rd quarter. California Public Employees Retirement System now owns 285,998 shares of the company’s stock valued at $1,038,000 after buying an additional 37,245 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in TherapeuticsMD by 178.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 53,050 shares of the company’s stock valued at $192,000 after buying an additional 34,000 shares during the last quarter. Hedge funds and other institutional investors own 63.59% of the company’s stock.

NASDAQ:TXMD opened at $2.30 on Friday. TherapeuticsMD Inc has a 12-month low of $1.82 and a 12-month high of $6.09. The company has a quick ratio of 2.69, a current ratio of 2.85 and a debt-to-equity ratio of 24.29. The firm has a market capitalization of $623.71 million, a P/E ratio of -3.90 and a beta of 1.65. The stock’s fifty day simple moving average is $2.65 and its 200-day simple moving average is $2.88.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. TherapeuticsMD had a negative return on equity of 430.28% and a negative net margin of 427.70%. The business had revenue of $8.21 million for the quarter, compared to analyst estimates of $8.05 million. During the same period last year, the company earned ($0.16) EPS. The firm’s revenue was up 136.6% on a year-over-year basis. As a group, equities research analysts expect that TherapeuticsMD Inc will post -0.67 earnings per share for the current year.

A number of research analysts have commented on TXMD shares. Oppenheimer set a $9.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research report on Thursday, August 22nd. Guggenheim began coverage on TherapeuticsMD in a research report on Monday, December 2nd. They issued a “buy” rating and a $5.00 price objective on the stock. Noble Financial restated a “buy” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research report on Friday, September 27th. Stifel Nicolaus reduced their price target on TherapeuticsMD from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. Finally, ValuEngine lowered TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $9.60.

In other TherapeuticsMD news, major shareholder Group L. P. Column bought 4,387 shares of TherapeuticsMD stock in a transaction on Wednesday, October 23rd. The shares were purchased at an average cost of $12.66 per share, for a total transaction of $55,539.42. Also, Director Brian Bernick bought 36,000 shares of TherapeuticsMD stock in a transaction on Friday, October 25th. The shares were acquired at an average price of $2.75 per share, for a total transaction of $99,000.00. Following the completion of the acquisition, the director now owns 98,000 shares of the company’s stock, valued at approximately $269,500. The disclosure for this purchase can be found here. Insiders bought a total of 112,387 shares of company stock worth $352,539 over the last 90 days. 18.91% of the stock is owned by corporate insiders.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Recommended Story: Outstanding Shares

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.